WuXi XDC Cayman, Inc. is an investment holding company, which engages in research, discovery, development, and manufacturing of the drug substances and drug products of antibody drug conjugates and other bio conjugates. The company is headquartered in Wuxi, Jiangsu and currently employs 2,270 full-time employees. The company went IPO on 2023-11-17. The firm's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The firm provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The firm principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.
02268.HK stock price ended at $70.85 on 金曜日, after dropping 2.81%
On the latest trading day Jan 16, 2026, the stock price of 02268.HK fell by 2.81%, dropping from $73.00 to $70.85. During the session, the stock saw a volatility of 6.92%, with prices oscillating between a daily low of $68.60 and a high of $73.35. On the latest trading day, the trading volume for 02268.HK rose by 34.4K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 6.2M shares were traded, with a market value of approximately $88.9B.